Results 141 to 150 of about 114,798 (264)

Farnesoid X Receptor: A New Player in Glucose Metabolism? [PDF]

Endocrinology, 2005
Cariou, B, Duran-Sandoval, D, Kuipers, F, Staels, B   +3 more
openaire   +3 more sources

Characterization of porcine pregnane X receptor, farnesoid X receptor and their splice variants

Experimental Biology and Medicine, 2010
The pregnane X receptor (PXR; NR1I2) and the farnesoid X receptor (FXR; NR1H4) regulate the expression of many major metabolic enzymes. With the pig being used as a model for humans in metabolic and toxicological studies and also an important food animal, we characterized the transactivation profile of the porcine orthologs of these receptors, pgPXR ...
Matthew A, Gray, Callie B, Pollock, Lawrence B, Schook, E James, Squires   +3 more
openaire   +2 more sources

Role of gut microbiota in the development of non-alcoholic fatty liver disease

Liver Research, 2019
Non-alcoholic fatty liver disease (NAFLD) is a chronic liver disease characterized by hepatic steatosis in the absence of other causes, such as chronic alcohol consumption, that cause secondary hepatic fat accumulation.
Xuemei Wang, Jialin Xia, Changtao Jiang
doaj   +1 more source

Hepatic GCGR is required for the superior weight loss and metabolic effects of a structurally related analogue of the dual GCGR/GLP‐1R agonist survodutide in mice

Diabetes, Obesity and Metabolism, EarlyView.
Fen Long, Tenagne D. Challa, Vissarion Efthymiou, Manuel Klug, Thomas Klein, Heike Neubauer, Christian Wolfrum, Carla Horvath   +7 more
wiley   +1 more source

Can Pharmacologic Therapy Induce Histologic Improvement in Non-alcoholic Steatohepatitis?

The Korean Journal of Gastroenterology, 2016
Articles: Farnesoid X Nuclear Receptor Ligand Obeticholic Acid for Non-cirrhotic, Non-alcoholic Steatohepatitis (FLINT): a Multicentre, Randomised, Placebo-controlled Trial (Lancet 2015;385:956-965) Liraglutide Safety and Efficacy in Patients with Non ...
Nae-Yun Heo
doaj   +1 more source

Vitamin D to reduce liver fibrosis in non-alcoholic fatty liver disease [PDF]

, 2017
BACKGROUND: As the prevalence of metabolic risk factors in the American population has increased over time, so too has the diagnoses of non-alcoholic fatty liver disease (NAFLD).
Fox, Ryan
core  

Western diet induces Paneth cell defects through microbiome alterations and farnesoid X receptor and type I interferon activation.

Cell Host and Microbe, 2021
Ta-Chiang Liu, Justin T. Kern, U. Jain, Naomi M. Sonnek, Shanshan Xiong, Katherine F. Simpson, K. VanDussen, Emma S. Winkler, T. Haritunians, Atika Malique, Qiuhe Lu, Y. Sasaki, C. Storer, M. Diamond, R. Head, D. McGovern, T. Stappenbeck   +16 more
semanticscholar   +1 more source

Farnesoid X Receptor as a potential protein target for mushroom LMW compounds: virtual screening using molecular docking [PDF]

, 2017
Farnesoid X receptor (FXR) is a nuclear receptor protein involved in controlling several metabolic pathways, with bile acids as his natural ligands. FXR functions as a sensor for bile acids, thus promoting their clearance by controlling expression of ...
Abreu, Rui M.V., Ferreira, Isabel C.F.R.
core  

A new perspective on NAFLD: Focusing on the crosstalk between peroxisome proliferator-activated receptor alpha (PPARα) and farnesoid X receptor (FXR).

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2022
Shipeng Zhou, Huimin You, Shuting Qiu, Dawei Yu, Yan Bai, Jincan He, Huan Cao, Qishi Che, Jiao Guo, Zhengquan Su   +9 more
semanticscholar   +1 more source

Farnesoid X receptor agonist tropifexor attenuates cholestasis in a randomised trial in patients with primary biliary cholangitis

JHEP Reports, 2022
C. Schramm, H. Wedemeyer, A. Mason, G. Hirschfield, C. Levy, K. Kowdley, P. Milkiewicz, E. Janczewska, E. Malova, J. Sanni, P. Koo, Jin Chen, S. Choudhury, L. Klickstein, M. Badman, David Jones   +15 more
semanticscholar   +1 more source